NCT04445311Unknown2 期
Use of Ivermectin as a Therapeutic Option for Patients With COVID-19
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- time to be symptoms free
研究概览
简要总结
confirmed cases with COVID-19 will receive ivermectin as a therapeutic option as well as standard of care treatment and will be compared to those that will receive only standard of care ttt
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •COVID-19 patients during period of the study more than 18 years old
排除标准
- •refuse to participate pregnancy or lactation hypersensitivity to ivermectin receive any drug with interaction with ivermectin
研究组 & 干预措施
Ivermectin group
Experimental
group that will receive ivermectin plus standard of care ttt
干预措施: Ivermectin (Drug)
结局指标
主要结局
time to be symptoms free
时间窗: within 21 days after enrollment
duration from day 1 symptoms till 3 days without symptoms
次要结局
- Mechanical ventilation(within 21 days after enrollement)
- hospitalization(within 21 days after enrollement)
- length of stay(within one month days after enrollement)
- mortality(within one month days after enrollement)
研究者
Waheed Shouman
professor of chest diseases
Zagazig University
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Ivermectin Reproposing for Mild Stage COVID-19 OutpatientsCovid19SARS (Severe Acute Respiratory Syndrome)NCT04784481Ministry of Public Health, Argentina254
Unknown
2 期
The (HD)IVACOV Trial (The High-Dose IVermectin Against COVID-19 Trial)Covid19NCT04712279Corpometria Institute294
撤回
3 期
Outpatient Use of Ivermectin in COVID-19Covid19NCT04530474Temple University
Unknown
不适用
Efficacy of Ivermectin in COVID-19COVIDNCT04392713Combined Military Hospital, Pakistan100
已完成
2 期
Ivermectin as a Novel Therapy in COVID-19 TreatmentCOVIDNCT04403555Tanta University164